(PRWEB) February 22, 2013
The acquisition of the Warnex Bioanalytical Services division allows Biotrial to broaden its drug development services to its international clients, giving them access to the full spectrum of Bioanalytical services to support preclinical and clinical development, including generics product development. To complement the service offering, Warnex clients now have access to the large range of existing Biotrial drug development services.
The new Biotrial addition includes: a team of highly experienced experts including a staff of over 70, more than 250 validated assays, 25 000 sq. ft. cutting edge laboratories and work stations, over 20 Mass Spectrometers and a validated Watson® LIMS.
BBS services have a SCC certification; have been audited by the FDA and AGES regulatory agencies. Services offered include: method development & validation, preclinical, bioavailability and bioequivalence studies, as well as therapeutic drug monitoring.
Jean-Marc Gandon, Pharm.D., President & CEO of Biotrial, says: “We have been looking for many years to find the right partner to complement our offer with sample analysis so that our customers could benefit from a full package in their process of developing new drugs or generics. Because of its ability to meet the growing needs of the pharmaceutical industry and to use the latest technology Warnex became an obvious choice. Biotrial is committed to continue providing the excellent service and quality of science for which the Montreal site is known for, by continuing its investment in the latest state-of-the-art equipment.”
Michael Mancini, Ph.D., BBS Inc. President, affirms: “It has been a very smooth transition and we are particularly excited to officially be a part of the Biotrial team. There is no change in management or staff and for us it is ‘business as usual.’ Being a part of such an international and well recognized CRO ensures that we will continue to expand our service offering as we have been doing for so many years.”
With the Bioanalytical acquisition Biotrial continues its expansion into the North American market which, will be complemented by the opening of an additional Clinical Unit in New Jersey later this year.
Founded in 1989, Biotrial is a leading CRO specialized in Early Development with a large range of services from Non-Clinical Pharmacology, Phase I studies, Phase II-IV Trial Management, Bioanalytical analysis, Oncology, Data Management, Biostatistics, ECG & Imaging Core Lab (QT/QTc Trials, Psychometric Testing, Imaging, EEG/PSG Assessment), Regulatory Affairs to Medical Writing.
Based in France, Belgium, the United Kingdom, Canada and the United States, Biotrial performs hundreds of studies a year and offers tailor-made solutions to Biotech and Pharmaceutical companies.
For further information please contact Anne Peron at [+33] (0)2 99 599 191 or visit [http://www.biotrial.com.